<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03698825</url>
  </required_header>
  <id_info>
    <org_study_id>MP-GC-01</org_study_id>
    <nct_id>NCT03698825</nct_id>
  </id_info>
  <brief_title>TEW-7197 With Paclitaxel for the Treatment of Metastatic Gastric Cancer</brief_title>
  <official_title>An Open-label, Multicenter Phase Ib/2a Study of TEW-7197 (Vactosertib) Plus Weekly Paclitaxel as Second-line Treatment for Metastatic Gastric Adenocarcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MedPacto, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>MedPacto, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, single arm study evaluating the safety and tolerability of TEW-7197 in
      combination with paclitaxel in metastatic gastric cancer patients.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 20, 2018</start_date>
  <completion_date type="Anticipated">June 20, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 20, 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Tolerated Dose (MTD)</measure>
    <time_frame>4 weeks</time_frame>
    <description>To define the MTD and determine RP2D</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants with treatment-related adverse events assessed by NCI CTCAE v5.0</measure>
    <time_frame>from screening through study completion (up to 28 days after the last dose of TEW-7197), an average of 1 year.</time_frame>
    <description>To evaluate safety profile of TEW-7197 with regards to frequency, type, grade, and seriousness, and causality of treatment-related clinical and laboratory adverse events including, but not limited to, AST, ALT, total bilirubin, serum creatinine, etc.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>every 2 cycles (8 weeks) and end-of-treatment (EOT) time point. EOT is defined as within 7 days from the last dose of study medication by the protocol.</time_frame>
    <description>Overall survival (months, median) defined by RECIST 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response</measure>
    <time_frame>every 2 cycles (8 weeks) and end-of-treatment (EOT) time point. EOT is defined as within 7 days from the last dose of study medication by the protocol.</time_frame>
    <description>Objective response rate (%) defined by RECIST 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>pharmacokinetics of TEW-7197</measure>
    <time_frame>At cycle 1 (each cycle is 28 days)</time_frame>
    <description>Peak Plasma Concentration (Cmax) of TEW-7197</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>pharmacokinetics of TEW-7197</measure>
    <time_frame>At cycle 1 (each cycle is 28 days)</time_frame>
    <description>Area under the plasma concentration versus time curve (AUC) of TEW-7197</description>
  </secondary_outcome>
  <other_outcome>
    <measure>pSMAD as a pharmacodynamic marker</measure>
    <time_frame>At baseline and cycle 1 (each cycle is 28 days)</time_frame>
    <description>pSMAD in peripheral blood mononuclear cell determined by immunohistochemistry</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">62</enrollment>
  <condition>Metastatic Gastric Cancer</condition>
  <arm_group>
    <arm_group_label>Dose Escalation of TEW-7197</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TEW-7191 will be given twice daily (BID) for 5 days followed by 2 days off with a cycle of 4 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TEW-7197</intervention_name>
    <description>TEW-7197 50mg tablets + Paclitaxel 80 mg/m2 D1, 8, 15 q 4 weeks TEW-7197 dose will be determined through this dose escalation study</description>
    <arm_group_label>Dose Escalation of TEW-7197</arm_group_label>
    <other_name>vactosertib</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically or cytologically confirmed metastatic gastric adenocarcinoma

          -  ECOG Performance Status &lt;2

          -  Patients who have disease progression after treatment with all available therapies
             including fluoropyrimidine and oxaliplatin or trastuzumab in case HER2 positive.

          -  Confirmation of measurable disease based on RECIST 1.1 by investigators at Screening

          -  Patients who meet below laboratory inclusion criteria Bilirubin&lt; 1.5xULN (upper limit
             of normal) Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) &lt; 3xULN
             (&lt;5xULN in case of hepatic metastasis) Serum creatinine &lt; 1.5xULN Absolute neutrophil
             count 1,000 cells/µL or more Platelet count 80,000/µL or more Hemoglobin count 9.0
             g/dL or more

          -  Capable of giving signed informed consent which includes compliance with the
             requirements and restrictions listed in the informed consent form (ICF) and in this
             protocol

        Exclusion Criteria:

          -  Patients who have received total gastrectomy

          -  Any unresolved toxicity NCI CTCAE Grade ≥2 from previous anticancer therapy

          -  Has received systemic anti-cancer therapy within 2 weeks prior to screening

          -  Has received major surgical procedure or radiation therapy within 4 weeks prior to
             screening

          -  Has received investigational agents for the cancer therapy and has not passed at least
             5 times of the half life of the agents.

          -  Previous treatment of paclitaxel or any agents targeting TGF-β signaling pathway

          -  Unable to swallow tablets

          -  Known CNS metastases and/or leptomeningeal involvement

          -  Has additional concurrent malignancy or has diagnosed another malignancy within 3
             years prior to screening excluding basal cell carcinoma, papillary thyroid cancer, or
             carcinoma in situ

          -  Uncontrolled congestive heart failure or myocardial infarction

          -  A women of childbearing potential (WOCBP) who has a positive urine pregnancy test, and
             male or female patients of reproductive potential who are not willing to employ
             effective birth control during the intervention and safety follow up period

          -  Child-Pugh B or C

          -  Judgment by the Investigator that the patient should not participate in the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sunjin Hwang, MD</last_name>
    <role>Study Director</role>
    <affiliation>MedPacto, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Insun Baek</last_name>
    <phone>+82-70-8610-2727</phone>
    <email>insun.baek@medpacto.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Yonsei University</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>September 27, 2018</study_first_submitted>
  <study_first_submitted_qc>October 4, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 9, 2018</study_first_posted>
  <last_update_submitted>May 4, 2020</last_update_submitted>
  <last_update_submitted_qc>May 4, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 6, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

